Cannabis medicine
June 22, 2010
THE world’s first prescription
cannabis medication, Sativex, has
been launched today by GW
Pharmaceuticals in the UK.
Designed for the treatment of
spasticity caused by multiple sclerosis,
Sativex has received full UK regulatory
approval, and contains two active
cannabinoid ingredients; THC
(delta-9-tetrahydrocannabinol) and
CBD (cannabidiol).
Delivered as a oromucosal spray,
GW Pharmaceuticals created Sativex
in response to calls from people
with MS for a cannabis-based medicine.
Sativex works to alleviate the
symptoms of both spasms and
cramping associated with MS spasticity,
and took 11 years to develop.
Moving forward, it is most likely
Spain will be the next country to
approve Sativex, and GW is
expected to launch approval
applications for its distribution in
other EU nations later this year.
The above article was sent to subscribers in Pharmacy Daily's issue from 22 Jun 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 22 Jun 10
